Louisiana HB 152 (2026 Regular Session), as introduced, proposes to amend the Uniform Controlled Dangerous Substances Law by enacting new Schedule I opiate entries at R.S. 40:964(Schedule I)(A)(108) through (120). The proposal would add a list of specified opioids/synthetic opioids (including certain nitazenes and fentanyl analog-related substances) to Schedule I, and directs the Louisiana State Law Institute to alphabetize/renumber the schedule entries. If enacted, impacted organizations would need to update controlled-substance lists and compliance controls tied to Louisiana Schedule I status.
Louisiana enacted Act No. 121 (HB 15, 2025), amending the Uniform Controlled Dangerous Substances Law (UCDSL) to add new substances to Schedule I (R.S. 40:964). The act adds N-Desethyl isotonitazene and etonitazepine as Schedule I opiates, and ethylphenidate as a Schedule I stimulant, and directs the Louisiana State Law Institute to renumber/alphabetize schedule entries. Compliance teams (e.g., healthcare/pharmacy, law enforcement, forensic labs, institutions with controlled-substance controls) should update controlled substance screening lists, handling/procurement controls, and any internal policies tied to Schedule I status.
Louisiana enacted SB 154 (2025 Regular Session) to amend the Uniform Controlled Dangerous Substances Law by adding kratom’s primary alkaloids—7-hydroxymitragynine and mitragynine—to Schedule I (R.S. 40:964, miscellaneous schedule section referenced in the research data). The act also creates a new statutory offense, R.S. 40:966.1, addressing unlawful possession, production, or distribution of kratom, and includes related changes referenced in the enrolled act text. Compliance teams should update controlled-substance and prohibited-ingredient screens, product compliance determinations (especially for kratom-containing products), and Louisiana-specific legal risk assessments for possession/distribution and retail controls.